Caribou Biosciences (NASDAQ:CRBU) and Pharvaris (NASDAQ:PHVS) Head to Head Survey

Caribou Biosciences (NASDAQ:CRBU) and Pharvaris (NASDAQ:PHVS) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, valuation, risk, institutional ownership, dividends, profitability and analyst recommendations.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Caribou Biosciences and Pharvaris, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Caribou Biosciences	1	0	2	1	2.75
Pharvaris	1	2	10	0	2.69

Caribou Biosciences currently has a consensus target price of $8.67, indicating a potential upside of 336.61%. Pharvaris has a consensus target price of $49.18, indicating a potential upside of 60.83%. Given Caribou Biosciences’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Caribou Biosciences is more favorable than Pharvaris.

Profitability

This table compares Caribou Biosciences and Pharvaris’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Caribou Biosciences	-1,189.14%	-84.17%	-60.51%
Pharvaris	N/A	-67.56%	-61.13%

Institutional & Insider Ownership

77.5% of Caribou Biosciences shares are owned by institutional investors. 8.5% of Caribou Biosciences shares are owned by company insiders. Comparatively, 11.8% of Pharvaris shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Risk and Volatility

Caribou Biosciences has a beta of 2.27, suggesting that its stock price is 127% more volatile than the S&P 500. Comparatively, Pharvaris has a beta of -2.34, suggesting that its stock price is 334% less volatile than the S&P 500.

Valuation and Earnings

This table compares Caribou Biosciences and Pharvaris”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Caribou Biosciences	$11.16 million	17.64	-$148.12 million	($1.42)	-1.40
Pharvaris	N/A	N/A	-$198.79 million	($3.18)	-9.62

Caribou Biosciences has higher revenue and earnings than Pharvaris. Pharvaris is trading at a lower price-to-earnings ratio than Caribou Biosciences, indicating that it is currently the more affordable of the two stocks.

Summary

Caribou Biosciences beats Pharvaris on 10 of the 14 factors compared between the two stocks.

About Caribou Biosciences

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.

About Pharvaris

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.